Lipum AB (OSTO:LIPUM) Debt-to-Equity : 0.25 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lipum AB Debt-to-Equity?

Lipum AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr10.02 Mil. Lipum AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr1.76 Mil. Lipum AB's Total Stockholders Equity for the quarter that ended in Sep. 2024 was kr47.75 Mil. Lipum AB's debt to equity for the quarter that ended in Sep. 2024 was 0.25.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Lipum AB's Debt-to-Equity or its related term are showing as below:

OSTO:LIPUM' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.37 Med: 0.08 Max: 0.53
Current: 0.25

During the past 5 years, the highest Debt-to-Equity Ratio of Lipum AB was 0.53. The lowest was -0.37. And the median was 0.08.

OSTO:LIPUM's Debt-to-Equity is ranked worse than
60.12% of 1023 companies
in the Biotechnology industry
Industry Median: 0.14 vs OSTO:LIPUM: 0.25

Lipum AB Debt-to-Equity Historical Data

The historical data trend for Lipum AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipum AB Debt-to-Equity Chart

Lipum AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.46

0.06

0.39

Lipum AB Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial														0.12	0.39	-0.37	0.04	0.25

Competitive Comparison of Lipum AB's Debt-to-Equity

For the Biotechnology subindustry, Lipum AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lipum AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipum AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Lipum AB's Debt-to-Equity falls into.

Lipum AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Lipum AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	1.761)	/	4.572
	=	0.39

Lipum AB's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.017	+	1.761)	/	47.748
	=	0.25

Lipum AB (OSTO:LIPUM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Lipum AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Lipum AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipum AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipum AB (OSTO:LIPUM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tvistevagen 48 C, Umea, SWE, 907 36

Website

https://www.lipum.se

Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of a novel treatment for chronic inflammatory diseases. The candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule (BSSL) of the immune system. The development is supported by solid pre-clinical data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need.

Lipum AB Headlines

No Headlines